For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | - | 0 | - | - |
| Research and development | 187,808 | 191,608 | 423,576 | 429,747 |
| General and administrative | 527,466 | 556,467 | 614,910 | 521,274 |
| Total operating expenses | 715,274 | 748,075 | 1,038,486 | 951,021 |
| Loss from operations | -715,274 | -748,075 | -1,038,486 | -951,021 |
| Change in fair value of warrant liability | -1,212 | -902 | -1,355 | 9,974 |
| Interest income | 47,325 | 6,654 | 20,039 | 19,993 |
| Total other income | 48,537 | 7,556 | 21,394 | 10,019 |
| Net loss | -666,737 | -740,519 | -1,017,092 | -941,002 |
| Non cash deemed dividend | - | - | - | 3,212,504 |
| Net loss attributable to common stockholders | -666,737 | - | - | -4,153,506 |
| Loss per share - basic | -0.37 | -1.33 | -0.32 | -2.37 |
| Loss per share - diluted | -0.37 | -1.33 | -0.32 | -2.37 |
| Weighted average shares outstanding - basic | 1,795,097 | 557,787 | 3,183,191 | 1,753,409 |
| Weighted average shares outstanding - diluted | 1,795,097 | 557,787 | 3,183,191 | 1,753,409 |
Bone Biologics Corp (BBLG)
Bone Biologics Corp (BBLG)